Table 2. Open in new tab Clinical...

	MACE	Major bleeding
Landmark 1
≥12 months (n = 1730)	282.1 ± 120.3	357 (20.6)	267.2	103 (6.0)	77.1	77 (4.5)	57.6	158 (9.1)	118.3	66 (3.8)	49.4	110 (6.4)	82.3
<12 months (n = 516)	278.3 ± 122.1	144 (27.9)	366.3	53 (10.3)	134.8	23 (4.5)	58.5	50 (9.7)	127.2	29 (5.6)	73.8	23 (4.5)	58.5
Landmark 2
≥15 months (n = 1240)	291.0 ± 113.6	219 (17.7)	221.7	79 (6.4)	80.0	43 (3.5)	43.5	84 (6.8)	85.0	38 (3.1)	38.5	71 (5.7)	71.9
<15 months (n = 685)	284.3 ± 118.2	152 (22.2)	285.1	56 (8.2)	105.0	27 (3.9)	50.6	49 (7.2)	91.9	35 (5.1)	65.6	33 (4.8)	61.9
Landmark 3
≥18 months (n = 963)	292.4 ± 115.6	155 (16.1)	201.0	56 (5.8)	72.6	30 (3.1)	38.9	66 (6.9)	85.6	22 (2.3)	28.5	56 (5.8)	72.6
<18 months (n = 729)	289.0 ± 113.9	145 (19.9)	251.4	65 (8.9)	112.7	26 (3.6)	45.1	42 (5.8)	72.8	28 (3.8)	48.5	33 (4.5)	57.2

MACE

Major bleeding

Overall

Mortality

Nonfatal MI

Revascularization

Stroke

Follow-up duration (days)

No. of events,^an (%)

Incidence^b

No. of events, n (%)

Incidence

No. of events, n (%)

Incidence

No. of events, n (%)

Incidence

No. of events, n (%)

Incidence

No. of events, n (%)

Incidence

Landmark 1

≥12 months (n = 1730)

282.1 ± 120.3

357 (20.6)

267.2

103 (6.0)

77.1

77 (4.5)

57.6

158 (9.1)

118.3

66 (3.8)

49.4

110 (6.4)

82.3

<12 months (n = 516)

278.3 ± 122.1

144 (27.9)

366.3

53 (10.3)

134.8

23 (4.5)

58.5

50 (9.7)

127.2

29 (5.6)

73.8

23 (4.5)

58.5

Landmark 2

≥15 months (n = 1240)

291.0 ± 113.6

219 (17.7)

221.7

79 (6.4)

80.0

43 (3.5)

43.5

84 (6.8)

85.0

38 (3.1)

38.5

71 (5.7)

71.9

<15 months (n = 685)

284.3 ± 118.2

152 (22.2)

285.1

56 (8.2)

105.0

27 (3.9)

50.6

49 (7.2)

91.9

35 (5.1)

65.6

33 (4.8)

61.9

Landmark 3

≥18 months (n = 963)

292.4 ± 115.6

155 (16.1)

201.0

56 (5.8)

72.6

30 (3.1)

38.9

66 (6.9)

85.6

22 (2.3)

28.5

56 (5.8)

72.6

<18 months (n = 729)

289.0 ± 113.9

145 (19.9)

251.4

65 (8.9)

112.7

26 (3.6)

45.1

42 (5.8)

72.8

28 (3.8)

48.5

33 (4.5)

57.2

	MACE	Major bleeding
Landmark 1
≥12 months (n = 1730)	282.1 ± 120.3	357 (20.6)	267.2	103 (6.0)	77.1	77 (4.5)	57.6	158 (9.1)	118.3	66 (3.8)	49.4	110 (6.4)	82.3
<12 months (n = 516)	278.3 ± 122.1	144 (27.9)	366.3	53 (10.3)	134.8	23 (4.5)	58.5	50 (9.7)	127.2	29 (5.6)	73.8	23 (4.5)	58.5
Landmark 2
≥15 months (n = 1240)	291.0 ± 113.6	219 (17.7)	221.7	79 (6.4)	80.0	43 (3.5)	43.5	84 (6.8)	85.0	38 (3.1)	38.5	71 (5.7)	71.9
<15 months (n = 685)	284.3 ± 118.2	152 (22.2)	285.1	56 (8.2)	105.0	27 (3.9)	50.6	49 (7.2)	91.9	35 (5.1)	65.6	33 (4.8)	61.9
Landmark 3
≥18 months (n = 963)	292.4 ± 115.6	155 (16.1)	201.0	56 (5.8)	72.6	30 (3.1)	38.9	66 (6.9)	85.6	22 (2.3)	28.5	56 (5.8)	72.6
<18 months (n = 729)	289.0 ± 113.9	145 (19.9)	251.4	65 (8.9)	112.7	26 (3.6)	45.1	42 (5.8)	72.8	28 (3.8)	48.5	33 (4.5)	57.2

Table 2.

Open in new tab

Clinical outcomes according to the status of DAPT in landmark analyses

	MACE											Major bleeding
		Overall		Mortality		Nonfatal MI		Revascularization		Stroke
	Follow-up duration (days)	No. of events,^an (%)	Incidence^b	No. of events, n (%)	Incidence	No. of events, n (%)	Incidence	No. of events, n (%)	Incidence	No. of events, n (%)	Incidence	No. of events, n (%)	Incidence
Landmark 1
≥12 months (n = 1730)	282.1 ± 120.3	357 (20.6)	267.2	103 (6.0)	77.1	77 (4.5)	57.6	158 (9.1)	118.3	66 (3.8)	49.4	110 (6.4)	82.3
<12 months (n = 516)	278.3 ± 122.1	144 (27.9)	366.3	53 (10.3)	134.8	23 (4.5)	58.5	50 (9.7)	127.2	29 (5.6)	73.8	23 (4.5)	58.5
Landmark 2
≥15 months (n = 1240)	291.0 ± 113.6	219 (17.7)	221.7	79 (6.4)	80.0	43 (3.5)	43.5	84 (6.8)	85.0	38 (3.1)	38.5	71 (5.7)	71.9
<15 months (n = 685)	284.3 ± 118.2	152 (22.2)	285.1	56 (8.2)	105.0	27 (3.9)	50.6	49 (7.2)	91.9	35 (5.1)	65.6	33 (4.8)	61.9
Landmark 3
≥18 months (n = 963)	292.4 ± 115.6	155 (16.1)	201.0	56 (5.8)	72.6	30 (3.1)	38.9	66 (6.9)	85.6	22 (2.3)	28.5	56 (5.8)	72.6
<18 months (n = 729)	289.0 ± 113.9	145 (19.9)	251.4	65 (8.9)	112.7	26 (3.6)	45.1	42 (5.8)	72.8	28 (3.8)	48.5	33 (4.5)	57.2

	MACE											Major bleeding
		Overall		Mortality		Nonfatal MI		Revascularization		Stroke
	Follow-up duration (days)	No. of events,^an (%)	Incidence^b	No. of events, n (%)	Incidence	No. of events, n (%)	Incidence	No. of events, n (%)	Incidence	No. of events, n (%)	Incidence	No. of events, n (%)	Incidence
Landmark 1
≥12 months (n = 1730)	282.1 ± 120.3	357 (20.6)	267.2	103 (6.0)	77.1	77 (4.5)	57.6	158 (9.1)	118.3	66 (3.8)	49.4	110 (6.4)	82.3
<12 months (n = 516)	278.3 ± 122.1	144 (27.9)	366.3	53 (10.3)	134.8	23 (4.5)	58.5	50 (9.7)	127.2	29 (5.6)	73.8	23 (4.5)	58.5
Landmark 2
≥15 months (n = 1240)	291.0 ± 113.6	219 (17.7)	221.7	79 (6.4)	80.0	43 (3.5)	43.5	84 (6.8)	85.0	38 (3.1)	38.5	71 (5.7)	71.9
<15 months (n = 685)	284.3 ± 118.2	152 (22.2)	285.1	56 (8.2)	105.0	27 (3.9)	50.6	49 (7.2)	91.9	35 (5.1)	65.6	33 (4.8)	61.9
Landmark 3
≥18 months (n = 963)	292.4 ± 115.6	155 (16.1)	201.0	56 (5.8)	72.6	30 (3.1)	38.9	66 (6.9)	85.6	22 (2.3)	28.5	56 (5.8)	72.6
<18 months (n = 729)	289.0 ± 113.9	145 (19.9)	251.4	65 (8.9)	112.7	26 (3.6)	45.1	42 (5.8)	72.8	28 (3.8)	48.5	33 (4.5)	57.2

Follow-up durations are reported as the mean ± SD.

Number of events from landmark to the end of follow-up.

Number of events per 1000 patient-years, presented as whole numbers.

This Feature Is Available To Subscribers Only